Central to protective humoral immunity is the activation of B cells and their terminal differentiation into antibody-secreting plasma cells. Long-lived plasma cells (LLPC) may survive for years to decades. Such long-lived plasma cells are also responsible for producing pathogenic antibodies that cause a variety of challenges such as autoimmunity, allograft rejection, and drug neutralization. Up to now, various therapeutic strategies aimed at durably eliminating pathogenic antibodies have failed, in large part due to their inability to efficiently target LLPCs. Several antibody-based therapies have recently gained regulatory approval or are in clinical phases of development for the treatment of multiple myeloma, a malignancy of plasma cells. We discuss the exciting potential of using these emerging cancer immunotherapies to solve the antibody problem.

中文翻译：

---

在消除长寿浆细胞的道路上——“我们到了吗？”

保护性体液免疫的核心是 B 细胞的激活及其终末分化为分泌抗体的浆细胞。长寿浆细胞 (LLPC) 可能存活数年至数十年。这种长寿的浆细胞还负责产生致病性抗体，这些抗体会引起各种挑战，例如自身免疫、同种异体移植排斥和药物中和。到目前为止，旨在持久消除致病抗体的各种治疗策略都失败了，这在很大程度上是由于它们无法有效地靶向 LLPC。几种基于抗体的疗法最近获得了监管部门的批准或处于治疗多发性骨髓瘤（浆细胞恶性肿瘤）的临床开发阶段。